The co-founders of Fred Hutch's oncology therapeutics developer include Philip Greenberg who previously helped launch Juno Therapeutics.
Affini-T Therapeutics, a US-based cancer therapy spinout of Fred Hutchinson Cancer Research Center, has closed an oversubscribed $175m round featuring the centre itself and The Parker Institute for Cancer Immunotherapy. Leaps by Bayer, a subsidiary of pharmaceutical and chemicals group Bayer, and life sciences-focused investment firm Vida Ventures, which co-founded Affini-T, co-led the round, which…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
